John Maslowski – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Tue, 16 Aug 2022 09:39:56 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png John Maslowski – VJRegenMed https://mirror.vjregenmed.com 32 32 Innovations in treating rare diseases with gene therapies https://mirror.vjregenmed.com/video/z4-rx6xbpi0-innovations-in-treating-rare-diseases-with-gene-therapies/ Wed, 20 Apr 2022 16:45:46 +0000 http://13.40.107.223/video/z4-rx6xbpi0-innovations-in-treating-rare-diseases-with-gene-therapies/ John Maslowski, CCO, Forge Biologics, Columbus, OH, comments on the current treatment landscape for rare diseases, especially in the field of gene therapies. With a large number of rare diseases lacking any form of treatment, finding curative solutions for these rare diseases remain an unmet need. Finding a suitable clinical model is essential to develop treatments, especially when the natural history group in a clinical trial is preferable to placebo groups, as in the case of studies targeting Krabbe disease. Introducing closed automated systems in the manufacturing process will additionally enable the production of gene therapies in an economical manner. This interview took place at Advanced Therapies Week 2022.

]]>
Overcoming manufacturing issues in gene therapies for rare diseases https://mirror.vjregenmed.com/video/rm-nn1xd4ko-overcoming-manufacturing-issues-in-gene-therapies-for-rare-diseases/ Wed, 20 Apr 2022 16:45:46 +0000 http://13.40.107.223/video/rm-nn1xd4ko-overcoming-manufacturing-issues-in-gene-therapies-for-rare-diseases/ John Maslowski, CCO, Forge Biologics, Columbus, OH, discusses strategies to optimize the manufacturing of gene therapies for rare diseases. In addition to regulatory barriers, maintaining the consistency of the product is vital, especially when manufacturing occurs in large-scale bioreactors. To ensure the cost of production remains low and the patients’ needs are successfully met, he emphasizes the need to use automated analytical tools in a closed system. Assessing product quality via high throughput systems can expedite production times on a larger scale. This interview took place at Advanced Therapies Week 2022.

]]>
Meeting the growing demand for gene therapy manufacturing https://mirror.vjregenmed.com/video/nwsxppi0zb4-meeting-the-growing-demand-for-gene-therapy-manufacturing/ Wed, 20 Apr 2022 16:45:45 +0000 http://13.40.107.223/video/nwsxppi0zb4-meeting-the-growing-demand-for-gene-therapy-manufacturing/ John Maslowski, CCO, Forge Biologics, Columbus, OH, gives an overview of Forge Biologics’ plans to meet the increasing demand for gene therapies. The recent $80 million expansion of the manufacturing facilities at Forge Biologics with automated components and clean rooms will enable global expansion. Additional recruitment of personal and inhouse analytical services will also enhance current adeno-associated virus (AAV) vector production capabilities. This interview took place at Advanced Therapies Week 2022.

]]>
Treating Krabbe disease with FBX-101 https://mirror.vjregenmed.com/video/h4fvbgt7yx4-treating-krabbe-disease-with-fbx-101/ Thu, 17 Feb 2022 12:04:56 +0000 http://13.40.107.223/video/h4fvbgt7yx4-treating-krabbe-disease-with-fbx-101/ Krabbe disease is a rare genetic disorder caused by a deficiency of the enzyme galactocerebrosidase (GALC) and can result in mortality in infants. John Maslowski, CCO, Forge Biologics, Columbus, OH, provides a brief overview of FBX-101, an adeno-associated virus (AAV)-based gene therapy for patients with Krabbe disease. The therapy is currently being assessed in the Phase I/II RESKUE trial (NCT04693598), where patients also receive a bone marrow transplant. FBX-101 has demonstrated preliminary efficacy and the trial will additionally assess safety as well as mobility in patients. This interview took place at Advanced Therapies Week 2022.

]]>